Suppr超能文献

间充质基质/干细胞:癌症细胞靶向基因治疗的新时代。

Mesenchymal Stromal/Stem Cells: A New Era in the Cell-Based Targeted Gene Therapy of Cancer.

作者信息

Marofi Faroogh, Vahedi Ghasem, Biglari Alireza, Esmaeilzadeh Abdolreza, Athari Seyyed Shamsadin

机构信息

Department of Hematology, Tabriz University of Medical Sciences, Tabriz, Iran.

Research Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

出版信息

Front Immunol. 2017 Dec 18;8:1770. doi: 10.3389/fimmu.2017.01770. eCollection 2017.

Abstract

In recent years, in light of the promising potentials of mesenchymal stromal/stem cells (MSCs) for carrying therapeutic anticancer genes, a complete revisitation on old chemotherapy-based paradigms has been established. This review attempted to bring forward and introduce the novel therapeutic opportunities of using genetically engineered MSCs. The simplicities and advantages of MSCs for medical applications make them a unique and promising option in the case of cancer therapy. Some of the superiorities of using MSCs as therapeutic gene micro-carriers are the easy cell-extraction procedures and their abundant proliferation capacity without losing their main biological properties. Targeted therapy by using MSCs as the delivery vehicles of therapeutic genes is a new approach in the treatment of various types of cancers. Some of the distinct properties of MSCs, such as tumor-tropism, non-immunogenicity, stimulatory effect on the anti-inflammatory molecules, inhibitory effect on inflammatory responses, non-toxicity against the normal tissues, and easy processes for the clinical use, have formed the basis of attention to MSCs. They can be easily used for the treatment of damaged or injured tissues, regenerative medicine, and immune disorders. This review focused on the drugability of MSCs and their potential for the delivery of candidate anticancer genes. It also briefly reviewed the vectors and methods used for MSC-mediated gene therapy of malignancies. Also, the challenges, limitations, and considerations in using MSCs for gene therapy of cancer and the new methods developed for resolution of these problems are reviewed.

摘要

近年来,鉴于间充质基质/干细胞(MSCs)在携带治疗性抗癌基因方面具有广阔的潜力,人们对基于化疗的旧有模式进行了全面的重新审视。本综述试图提出并介绍使用基因工程化MSCs的新型治疗机会。MSCs在医学应用中的简便性和优势使其在癌症治疗中成为一个独特且有前景的选择。将MSCs用作治疗性基因微载体的一些优势在于细胞提取程序简便,且具有丰富的增殖能力,同时不会丧失其主要生物学特性。利用MSCs作为治疗性基因的递送载体进行靶向治疗是治疗各类癌症的一种新方法。MSCs的一些独特特性,如肿瘤嗜性、非免疫原性、对抗炎分子的刺激作用、对炎症反应的抑制作用、对正常组织无毒以及临床使用过程简便等,构成了人们关注MSCs的基础。它们可轻松用于治疗受损组织、再生医学和免疫紊乱。本综述重点关注了MSCs的药物可及性及其递送候选抗癌基因的潜力。还简要回顾了用于MSCs介导的恶性肿瘤基因治疗的载体和方法。此外,还综述了在使用MSCs进行癌症基因治疗时面临的挑战、限制和注意事项,以及为解决这些问题而开发的新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dee/5741703/2640afc44da6/fimmu-08-01770-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验